Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab + DMARDs in RA (ML21753)
NCT00773461Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2008
- Primary completion
- Jul 2010
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Tocilizumab + DMARDs with Placebo + DMARDs (2 arms). Primary endpoint: American College of Rheumatology 20% Response at 24 weeks. Started Oct 2008; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00773461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00773461.